Sunshine Heart Changes Course Again: Pauses Neuromodulation To Focus On Aquadex
Executive Summary
The company has switched from pursuing a counterpulsation technology to focusing on a fully implantable neuromodulation device, and is now directing its full attention to the recently acquired Aquadex FlexFlow ultrafiltration system for heart failure, all in a period of about three-to-four months.
You may also be interested in...
Exec Chat: CHF Solutions Focused On Expanding Access To Aquadex Ultrafiltration
Nestor Jaramillo, who just finished his first quarter as CEO of CHF Solutions, told Medtech Insight how his company is making its Aquadex ultrafiltration technology part of the standard of care for heart failure patients and others with dangerous fluid overload.
Sunshine Heart's CEO Departs As The Firm Faces Trial Challenges
The heart-assist device firm abruptly announced the departure of its CEO. Sunshine has faced multiple challenges, including slow enrollment and the need for protocol-ordered pause, with the pivotal trial for its C-Pulse system.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.